RAS genes are the most frequently mutated oncogenes in cancer. These mutations occur in
roughly half of the patients with colorectal cancer (CRC). RAS mutant tumors are resistant to …

Simple Summary Myelofibrosis is a disease arising from bone marrow driven by mutations in
stem cells, which results in progressive failure of marrow production in red and white blood …

SHP2 phosphatase promotes full activation of the RTK-dependent Ras/MAPK pathway. Its
mutations can drive cancer and RASopathies, a group of neurodevelopmental disorders …

SHP2 plays an important role in regulating cellular processes, and its pathogenic mutations
cause developmental disorders and are linked to cancer. SHP2 is a multidomain protein …

SHP2 is a positive regulator of the EGFR-dependent Ras/MAPK pathway. It
dephosphorylates a regulatory phosphorylation site in EGFR that serves as the binding site …

The human PTPN11 gene encodes for the src tyrosine phosphatase protein (SHP2) is now
gaining much attention in many disorders, particularly its oncogenic involvement in many …

Advances in immunotherapy have brought significant therapeutic benefits to many cancer
patients. Nonetheless, many cancer types are refractory to current immunotherapeutic …

Introduction The KRAS (G12C) mutation is the most common genetic mutation in North
American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C …

Hepatocellular carcinoma (HCC) is a severe and increasingly prevalent health issue
affecting individuals globally. Recent research endeavors in the clinical domains have lately …

Phosphate groups are known to belong to post-translational protein modifications.
Phosphorylation-mediated signaling events regulate many medical conditions, including …